22157.jpg
Corporate Reputation of Pharma in Canada, 2023/2024: The Views of 100 Canadian Patient Groups - Fair Pricing Policies, Transparency of Pricing, and Engaging Patients in R&D Among the Lowest-Scoring Indicators
26 juin 2024 09h25 HE | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024 - The Patient Perspective - Canada Edition - The Views of 100 Canadian Patient Groups" report has been...
Agile_Logo-color on white.jpg
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
26 juin 2024 07h45 HE | Agile Therapeutics, Inc.
Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to...
22157.jpg
Corporate Reputation of Pharma in 2023/2024: The Patient Perspective and Views of 2,500+ Patient Groups - Pharma Corporate Reputation Falls from COVID Highs
26 juin 2024 06h51 HE | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024: The Patient Perspective (Global Edition) - The Views of 2,500+ Patient Groups Worldwide" report has...
22157.jpg
Survey Results of 830+ Patient Groups on the Pharmaceutical Industry and Environmental, Social, and Governance (ESG) Practices
24 juin 2024 11h44 HE | Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Pharma and ESG: The Patient Perspective, 2023 - The Views of 832 Patient Groups from Around the World" report has been added to ...
Afrezza (inhaled insulin) in use
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
22 juin 2024 08h00 HE | MannKind
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
Global Medical Food Market
Global $38.9 Billion Medical Food Market by Category, Type, Form, Distribution Channel, Application, and Region - Forecast to 2030
21 juin 2024 09h15 HE | Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Medical Food Market 2024-2030" report has been added to ResearchAndMarkets.com's offering.The Medical Food Market size was estimated at USD...
22157.jpg
Patient Perspective of 520 Cancer Patient Groups on the Corporate Reputation of Pharma in 2023/2024: Roche Ranked 1st, AstraZeneca Ranked 2nd, and Pfizer Ranked 3rd
21 juin 2024 08h54 HE | Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024 - The Patient Perspective - Cancer Edition - The Views of 520 Cancer Patient Groups" report has been...
Herman Sintim, Purdue University
‘Like a hand fitting into a glove’: Purdue-engineered compound designed to treat drug-resistant acute myeloid leukemia
20 juin 2024 10h55 HE | Purdue Research Foundation
WEST LAFAYETTE, Ind., June 20, 2024 (GLOBE NEWSWIRE) -- Researchers at Purdue University’s College of Science have developed a patent-pending compound called HSN748 to treat drug-resistant acute...
Avextra Logo.png
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20 juin 2024 01h00 HE | Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines, is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...
Avextra Logo.png
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20 juin 2024 01h00 HE | Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...